Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...
Healthy Living with USA Health: Comprehensive Sickle Cell Center provides life changing Gene Therapy
MOBILE, Ala. (WALA) - Gene therapy for sickle cell disease (SCD) is a cutting-edge treatment that targets the root cause of the disorder—a genetic mutation in the HBB gene, which leads to the ...
Early proof-of-concept study of Gene Writer formulated in a LNP achieved an average of 24% of HBB rewriting in LT-HSCs in NHP, reaching anticipated therapeutic levels established by human mixed-donor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results